LncRNA CASC11 aggravates diabetic nephropathy via targeting FoxO1
CASC11 aggravates diabetic nephropathy
Abstract
Background: To explore the biological effects of CASC11 on aggravating diabetic nephropathy (DN) by regulating FoxO1 (forkhead transcription factor O1).
Methods: Serum levels of CASC11 and FoxO1 in DN patients were detected. The possibility of CASC11 in predicting the onset of DN was analyzed by depicting ROC curves. Correlation between CASC11 and FoxO1 was evaluated by Pearson correlation test. After intervening CASC11 and FoxO1 levels, changes in proliferative and migratory abilities in HG-induced kidney mesangial cells were determinedrespectively. Expression levels of TGF-β1 and Smads regulated by both CASC11 and FoxO1 were examined by Western blot.
Results: CASC11 was highly expressed in serum of DN patients, whereas FoxO1 was downregulated, showing a negative correlation. CASC11 may be a diagnostic marker for DN. It attenuated proliferative and migratory abilities in HG-induced kidney mesangial cells, and the inhibitory effects of CASC11 could be abolished by overexpression of FoxO1. Protein levels of TGF-β1 and Smads were positively regulated by CASC11, which were reversed by Smads regulation.
Conclusions: Through activating the TGF-β1/Smads signaling, CASC11 inhibits FoxO1 expression and thus induces the aggravation of DN.
References
1. Torok B, Toth I, Halmagyi G, Roth E. The donor kidney: III. Angio-architecture and function of the reimplanted kidney. Acta Chir Acad Sci Hung 1978; 19(2): 137-44.
2. Cho NH, Shaw JE, Karuranga S, Huang Y, Da RFJ, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pr 2018; 138: 271-81.
3. Dewanjee S, Bhattacharjee N. MicroRNA: A new generation therapeutic target in diabetic nephropathy. Biochem Pharmacol 2018; 155: 32-47.
4. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 2016; 17(1): 47-62.
5. Hanson RL, Craig DW, Millis MP, Yeatts KA, Kobes S, Pearson JV, et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 2007; 56(4): 975-83.
6. Millis MP, Bowen D, Kingsley C, Watanabe RM, Wolford JK. Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. Diabetes 2007; 56(12): 3027-32.
7. Baggaley KH, Fears R, Hindley RM, Morgan B, Murrell E, Thorne DE. Hypolipidemic analogues of ethyl 4-benzyloxybenzoate. J Med Chem 1977; 20(11): 1388-93.
8. Balkany TJ, Berman SA, Watson WJ. Sterile preparation of the external auditory canal with povidone-iodine. Otolaryngol Head Neck Surg (1979) 1979; 87(2): 258-60.
9. Ponugoti B, Dong G, Graves DT. Role of forkhead transcription factors in diabetes-induced oxidative stress. Exp Diabetes Res 2012; 2012: 939751.
10. Guo F, Zhang Y, Wang Q, Ren L, Zhou Y, Ma X, et al. Effects of FoxO1 on podocyte injury in diabetic rats. Biochem Bioph Res Co 2015; 466(2): 260-6.
11. Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010; 31(1): 68-74.
12. Xie C, Guo Y, Lou S. LncRNA ANCR Promotes Invasion and Migration of Gastric Cancer by Regulating FoxO1 Expression to Inhibit Macrophage M1 Polarization. Digest Dis Sci 2020:
13. Wang G, Wu B, Zhang B, Wang K, Wang H. LncRNA CTBP1-AS2 alleviates high glucose-induced oxidative stress, ECM accumulation, and inflammation in diabetic nephropathy via miR-155-5p/FOXO1 axis. Biochem Bioph Res Co 2020; 532(2): 308-14.
14. Goedegebure E, Koning SH, Hoogenberg K, Korteweg FJ, Lutgers HL, Diekman M, et al. Pregnancy outcomes in women with gestational diabetes mellitus diagnosed according to the WHO-2013 and WHO-1999 diagnostic criteria: a multicentre retrospective cohort study. Bmc Pregnancy Childb 2018; 18(1): 152.
15. Klebe B, Farmer C, Cooley R, de Lusignan S, Middleton R, O'Donoghue D, et al. Kidney disease management in UK primary care: guidelines, incentives and information technology. Fam Pract 2007; 24(4): 330-5.
16. Ni WJ, Tang LQ, Wei W. Research progress in signalling pathway in diabetic nephropathy. Diabetes-Metab Res 2015; 31(3): 221-33.
17. Sidaway P. Diabetic nephropathy: Heparanase mediates renal injury. Nat Rev Nephrol 2014; 10(9): 483.
18. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. Rna Biol 2013; 10(6): 925-33.
19. Liu JY, Yao J, Li XM, Song YC, Wang XQ, Li YJ, et al. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis 2014; 5: e1506.
20. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464(7291): 1071-6.
21. Stierle G. [Problems concerning the seriously ill and dying child]. Krankenpflege (Frankf) 1977; 31(10): 347-50.
22. Zhang Z, Zhou C, Chang Y, Zhang Z, Hu Y, Zhang F, et al. Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/beta-catenin pathway to promote growth and metastasis in colorectal cancer. Cancer Lett 2016; 376(1): 62-73.
23. Wu L, Zhang Y, Ma X, Zhang N, Qin G. The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol Biol Rep 2012; 39(9): 9085-93.
24. Cai J, Tian AX, Wang QS, Kong PZ, Du X, Li XQ, et al. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett 2015; 367(2): 129-37.
25. Kong FF, Qu ZQ, Yuan HH, Wang JY, Zhao M, Guo YH, et al. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. Oncol Rep 2014; 31(6): 2660-8.
26. Seoane J, Le HV, Shen L, Anderson SA, Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117(2): 211-23.
Copyright (c) 2023 Yun Zhang, Shuhan Shi, Changda Lin, Lishuang Che, Yuangen Li, Quanzuan Zeng, Weiyuan Lin
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.